Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 24.6821
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 13157775780.0
- FreeCF/Share 1.0821
- PFCF 54.7745
- PE 82.4653
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Why The Hims & Hers Health Rally Has Room To Run
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing customized care in Q1. Monthly online revenue per subscriber rose 50% YoY to $84, driven by high adoption of tailored daily treatments.
Read More
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
Read More
Hims & Hers: Outsized Subscription Growth Is Enviable - Premium Valuations
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Positive
The bulls have well defended Hims & Hers' recovery from the April 2025 bottom (near to our fair value estimates), thanks to the growing adoption of its personalized healthcare offerings. These have directly triggered the growing subscriber base/ Revenue per Average Subscriber, with the improved manufacturing/ operating scale contributing to the richer profit margins. This is significantly aided by the growing GLP-1 partnership and the regulatory exemption surrounding compounding personalization, lending support to the raised FY2025 guidance and ambitious 2030 targets.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
2 Reasons To Double Down On Hims & Hers Ahead Of August
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
I expected Hims & Hers' stock to break $50, and now I'm buckling up for another rally, with EMAs stacked bullishly at the moment. The company's partnership with Novo Nordisk and the ZAVA acquisition for European expansion should drive the next leg of growth. Wegovy sales and potential cheaper Ozempic offerings are set to boost revenue, with subscriber growth and ARPU at record highs despite macro headwinds.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
These 24 Stocks Are Ripe for a Short Squeeze
Published: June 12, 2025 by: Schaeffers Research
Sentiment: Neutral
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Read More
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Read More
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Read More
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Read More
Hims & Hers Stock: Buy the Dip or Wait It Out?
Published: June 05, 2025 by: MarketBeat
Sentiment: Positive
One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector.
Read More
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Read More
Why Is Hims & Hers Health (HIMS) Up 10.6% Since Last Earnings Report?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Read More
Which Telehealth Stock Should You Be Targeting?
Published: June 03, 2025 by: Schaeffers Research
Sentiment: Positive
Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
Read More
Top Stock Movers Now: Dollar General, Hims & Hers, Bumble, and More
Published: June 03, 2025 by: Investopedia
Sentiment: Positive
U.S. equities rose at midday as the markets continued to wait for more information about possible U.S. trade deals. The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly higher.
Read More
Hims & Hers Expands in Europe With Acquisition of ZAVA
Published: June 03, 2025 by: Investopedia
Sentiment: Positive
Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed.
Read More
Hims expands into Europe with Zava acquisition
Published: June 03, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Brandon Gomez reports on the latest news regarding Hims.
Read More
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Read More
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Hims & Hers expands into Europe with Zava acquisition
Published: June 03, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS), a leading US-based health and wellness platform, is expanding into Europe via its acquisition of telehealth platform and online pharmacy Zava. The company said the acquisition will expand its footprint in the UK and launch the company in Germany, France and Ireland, with additional markets expected soon.
Read More
Hims & Hers stock rockets on news of European launch
Published: June 03, 2025 by: Finbold
Sentiment: Positive
Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
Hims to acquire UK-based startup Zava as it expands international presence
Published: June 03, 2025 by: Reuters
Sentiment: Positive
Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.
Read More
Hims & Hers to acquire European telehealth platform in global expansion
Published: June 03, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava. The deal will expand Hims' services to Ireland, France and Germany and will grow its active customer base by roughly 50%.
Read More
Hims & Hers: Still Huge Potential Ahead
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 in February but has since settled at $49.47. Financials reveal a 111% YoY revenue increase to $586 million and a 77.5% rise in net income to $49.5 million.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims to cut 4% of workforce amid ban on weight-loss drug copies
Published: May 30, 2025 by: Reuters
Sentiment: Negative
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
Read More
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
Read More
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637